Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company uses proprietary platform technologies to engineer targeted, durable Treg cell therapies. Its lead program targets rheumatoid arthritis, with additional indications in development through a collaboration with Regeneron.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountUnknown
Unknown
Unknown
Sep 2024
Aug 2021
Sep 2020
Feb 2020
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
